ArticleBMC oral health2026
Short-term assessment of non-surgical periodontal therapy reduces oral pathogens and pro-inflammatory cytokines, enhancing clinical outcomes in patients with chronic kidney disease.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPeriodontal diseases have been reported to be associated with chronic kidney disease (CKD) progression. Thus, this study aimed to evaluate non-surgical periodontal therapy (NSPT) in patients with CKD disease progression by monitoring oral parameters, pathogen levels, cytokine profiles, and kidney function.
methodsForty-five participants (age 60.0 ± 8.5 years) were examined at baseline and at 3 months after NSPT for oral parameters, oral pathogens (Porphyromonas gingivalis, Fusobacterium nucleatum, Aggregatibacter actinomycetemcomitans, Candida albicans), cytokines (IL-6, IL-8, TNF-α, IL-10), and kidney functions (serum creatinine, eGFR, urine protein-creatinine ratio).
resultsAt baseline, the CKD patients were diagnosed with stage II-IV periodontitis and exhibited measurable periodontal pathogen levels (P. gingivalis, 1.2 log CFU/mL; F. nucleatum, 4.4 log CFU/mL; A. actinomycetemcomitans, 0.3 log CFU/mL; and C. albicans, 4.1 log CFU/mL). Concurrently, pro-inflammatory cytokine concentrations were recorded at 0.2-4.4 pg/mL for IL-6, 1.9-25.5 pg/mL for IL-8, and 0.0-26.1 pg/mL for TNF-α. Conversely, IL-10 levels ranged from 0.0 to 13.2 pg/mL. After 3 months of NSPT, the levels of pathogens (1.1-10.9 fold) and cytokines (1.2-2.6 fold) were significantly reduced, while IL-10 levels significantly increased (0.7-1.9 fold). The number of patients showing improvement for serum creatinine and urine protein-creatinine ratio in CKD patients was 59.1-71.4% and 60.9-90.0%, respectively.
conclusionOur findings suggest that NSPT may benefit CKD patients by reducing oral pathogens and inflammation while increasing IL-10. There was evidence of a possible trend towards enhanced kidney function in CKD patients treated with NSPT.
trial registrationThe study was registered in the Thai Clinical Trials Registry (TCTR20240516002; registered date 16 May 2024), Thailand.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.